Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease

dc.contributor.authorFlygel, Trym Thune
dc.contributor.authorHameiri-Bowen, Dan
dc.contributor.authorSimms, Victoria
dc.contributor.authorRowland-Jones, Sarah
dc.contributor.authorFerrand, Rashida Abbas
dc.contributor.authorBandason, Tsitsi
dc.contributor.authorYindom, Louis-Marie
dc.contributor.authorOdland, Jon Oyvind
dc.contributor.authorCavanagh, Jorunn Pauline
dc.contributor.authorFlaegstad, Trond
dc.contributor.authorSovershaeva, Evgeniya
dc.date.accessioned2024-04-11T07:37:53Z
dc.date.available2024-04-11T07:37:53Z
dc.date.issued2024-02
dc.descriptionSUPPORTING INFORMATION : FIGURE S1. Box plot of eNO at baseline and 48 weeks by trial group and overall. AZM, azithromycin; eNO, exhaled nitric oxide. TABLE S1. Baseline characteristics of participants by trial group. TABLE S2. Effect of azithromycin on levels of eNO after 48 weeks of treatment using a generalized linear model. eNO, exhaled nitric oxide.en_US
dc.description.abstractOBJECTIVES : Chronic lung disease is a recognized complication in children with HIV. Acute respiratory exacerbations (ARE) are common among this group and cause significant morbidity. Exhaled nitric oxide (eNO) is a known marker of local airway inflammation. We investigated the association between eNO and ARE, biomarkers of systemic inflammation, and the effect of azithromycin on eNO levels. METHODS : Individuals aged 6–19 years with HIV-associated chronic lung disease in Harare, Zimbabwe, were enrolled in a placebo-controlled randomized trial investigating the effect of 48-week azithromycin treatment on lung function and ARE. eNO levels and biomarkers were measured at inclusion and after treatment in a consecutively enrolled subset of participants. Linear regression and generalized linear models were used to study associations between eNO and ARE, biomarkers, and the effect of azithromycin on eNO levels. RESULTS : In total, 172 participants were included in this sub-study, 86 from the placebo group and 86 from the azithromycin group. Participants experiencing at least one ARE during follow-up had significantly higher eNO levels at baseline than participants who did not (geometric mean ratio 1.13, 95% confidence interval [CI] 1.03–1.24, p = 0.015), adjusted for trial arm, age, sex and history of tuberculosis. Matrix metalloproteinase (MMP)-3, -7, and -10 were significantly associated with higher baseline eNO levels. At 48 weeks, azithromycin treatment did not affect eNO levels (geometric mean ratio 0.86, 95% CI 0.72–1.03, p = 0.103). CONCLUSION : Higher baseline eNO levels were a risk factor for ARE. eNO was associated with proinflammatory biomarkers previously found to contribute to the development of chronic lung disease. The potential use of eNO as a marker of inflammation and risk factor for ARE in HIV-associated chronic lung disease needs further investigation.en_US
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)en_US
dc.description.librarianhj2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipNorges Forskningsråd; Global Health and Vaccination Research (GLOBVAC) programme; Helse Nord RHF; Wellcome Trust PhD Programme in Genomic Medicine and Statistics; Wellcome Trust; UK Medical Research Council; UK Department for International Development (DFID); European Union.en_US
dc.description.urihttp://wileyonlinelibrary.com/journal/hiven_US
dc.identifier.citationFlygel, T.T., Hameiri-Bowen, D., Simms, V., et al. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease. HIV Medicine 2024; 25(2): 223‐232. doi:10.1111/hiv.13565.en_US
dc.identifier.issn1464-2662 (print)
dc.identifier.issn1468-1293 (online)
dc.identifier.other10.1111/hiv.13565
dc.identifier.urihttp://hdl.handle.net/2263/95478
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rights© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.subjectAfricaen_US
dc.subjectBiomarkersen_US
dc.subjectChronic lung diseaseen_US
dc.subjectHuman immunodeficiency virus (HIV)en_US
dc.subjectInflammationen_US
dc.subjectAcute respiratory exacerbations (ARE)en_US
dc.subjectExhaled nitric oxide (eNO)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleExhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung diseaseen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 4 of 4
Loading...
Thumbnail Image
Name:
Flygel_Exhaled_2023.pdf
Size:
699.61 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Flygel_ExhaledFigS1_2023.pdf
Size:
80.05 KB
Format:
Adobe Portable Document Format
Description:
Figure S1
Loading...
Thumbnail Image
Name:
Flygel_ExhaledTabS1_2023.pdf
Size:
136.65 KB
Format:
Adobe Portable Document Format
Description:
Table S1
Loading...
Thumbnail Image
Name:
Flygel_ExhaledTabS2_2023.pdf
Size:
61.36 KB
Format:
Adobe Portable Document Format
Description:
Table S2

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: